The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML
AP-1 通路激活在 NK 细胞发育和 AML 衰竭编程中的作用
基本信息
- 批准号:10751755
- 负责人:
- 金额:$ 4.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAdultAutomobile DrivingBlood CellsCell LineCell MaturationCell SeparationCell physiologyCellsChromatinClinicalCre lox recombination systemDNA MethylationDataDefectDevelopmentDiagnosisEpigenetic ProcessFOS ProteinFamilyGene Expression ProfilingGenetic TranscriptionHematologic NeoplasmsHomeostasisHumanImmuneImmune EvasionImmunologic SurveillanceImmunotherapeutic agentImpairmentIn VitroInterferon Type IILymphoid CellMAPK8 geneMEK inhibitionMEKsMediatingMusMyelogenousNatural Killer CellsOutcomePathogenesisPathway interactionsPatient-Focused OutcomesPatientsPlayPost-Translational Protein ProcessingPrecursor Natural Killer CellProductionProteinsRegulationRoleSeriesSignal PathwaySignal TransductionSurvival RateTestingTherapeuticTranscriptional ActivationTreatment EfficacyWorkXenograft Modelactivating transcription factoracute myeloid leukemia cellcancer cellcheckpoint receptorsdesigndimerepigenetic profilingexhaustionfunctional disabilityimmune checkpointin vivoin vivo Modelinhibitorleukemialeukemia relapsemouse modelnovelp38 Mitogen Activated Protein Kinasepharmacologicpreservationpreventprogramssmall molecular inhibitorstem cellstargeted treatmenttherapeutic targettherapeutically effectivetranscription factortranscriptome sequencing
项目摘要
PROJECT SUMMARY/ABSTRACT
The 5-year overall survival rate for acute myeloid leukemia (AML) is less than 35%, making it the most fatal
leukemia in adults. Natural killer (NK) cells are a type of innate lymphoid cell (ILC) capable of recognizing and
killing malignant cells. We have previously demonstrated that NK cells are developmentally and functionally
impaired in AML. These impairments correlate to worse overall survival and clinical outcomes, highlighting the
importance of understanding the mechanisms by which AML alters NK cell development and function. To better
understand these defects, we assessed the transcriptional and epigenetic landscape of NK cells in AML and
discovered that mature NK cells from AML patients are globally hypomethylated when compared to normal
controls and have abnormal activation of activating protein-1 (AP-1). AP-1, which is a set of transcription factor
(TF) dimers primarily composed of Jun and Fos family proteins, has been shown to regulate ILC development
and homeostasis, chromatin accessibility, and immune cell exhaustion. The activity of AP-1 is regulated by
upstream mitogen activated protein kinases p38, JNK and ERK through transcription activation and post-
translational modifications. In this proposal, we will determine how the MEK/ERK signaling branch of the AP-1
signaling pathway contributes to NK cell defects in AML and whether development and function can be restored
through AP-1 pathway inhibition. We hypothesize that AP-1 signaling is a critical regulator of NK cell development
and function that becomes dysregulated in AML. These studies will first describe the mechanism(s) by which the
AP-1 pathway influences NK cell development in the setting of AML (Aim 1). We will use pharmacologic agents
as well as CRISPRcas9 editing to understand how aberrant AP-1 signaling skews human NK cell development.
We will also determine the functional consequences of aberrant AP-1 activation in mature NK cells (Aim 2).
Finally, we will assess the therapeutic efficacy of AP-1 pathway regulation in multiple in vivo models of AML (Aim
3). Results from these studies will further our mechanistic understanding of NK cell development in AML to better
inform therapeutic strategies.
项目总结/摘要
急性髓细胞白血病(AML)的5年总生存率低于35%,使其成为最致命的白血病
成人白血病自然杀伤(NK)细胞是一种能够识别和杀伤肿瘤细胞的先天性淋巴样细胞(ILC)。
杀死恶性细胞我们以前已经证明,NK细胞在发育和功能上是
在AML中受损。这些损伤与较差的总生存率和临床结局相关,突出了
了解AML改变NK细胞发育和功能的机制的重要性。更好地
了解这些缺陷后,我们评估了AML中NK细胞的转录和表观遗传格局,
发现与正常人相比,AML患者的成熟NK细胞总体上是低甲基化的
控制并具有激活蛋白-1(AP-1)的异常激活。AP-1是一组转录因子,
(TF)主要由Jun和Fos家族蛋白组成的二聚体已被证明可调节ILC的发育
和稳态、染色质可及性和免疫细胞耗竭。AP-1的活性受以下因素的调节:
上游有丝分裂原激活蛋白激酶p38、JNK和ERK通过转录激活和后
翻译修饰在这个提议中,我们将确定AP-1的MEK/ERK信号传导分支是如何被激活的。
信号通路有助于AML中的NK细胞缺陷以及发育和功能是否可以恢复
通过AP-1通路抑制。我们假设AP-1信号是NK细胞发育的关键调节因子
在AML中变得失调。这些研究将首先描述
AP-1通路影响AML背景下的NK细胞发育(目的1)。我们将使用药物
以及CRISPRcas 9编辑,以了解异常AP-1信号传导如何扭曲人类NK细胞发育。
我们还将确定成熟NK细胞中异常AP-1激活的功能后果(目的2)。
最后,我们将评估AP-1通路调节在AML的多种体内模型中的治疗功效(Aim
3)。这些研究的结果将进一步加深我们对AML中NK细胞发育机制的理解,
提供治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Erin G. Jeremy其他文献
Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies
阐明 MDM2 抑制剂 Navtemadlin 的作用机制 (MOA) 及其与 Gilteritinib 在骨髓恶性肿瘤中的协同作用
- DOI:
10.1182/blood-2022-159568 - 发表时间:
2022 - 期刊:
- 影响因子:20.3
- 作者:
Sara Elgamal;Tracy Clevenger;Michael Gulrajani;Jean P. Cheung;Erin G. Jeremy;Sydney Fobare;S. Orwick;E. Sass;E. Hertlein;Karilyn T. Larkin;T. Covey;Wayne P. Rothbaum;J. Byrd - 通讯作者:
J. Byrd
Type 3 Innate Lymphoid Cells Protect Leukemic Blasts from Natural Killer Cell Cytotoxicity in Acute Myeloid Leukemia
- DOI:
10.1182/blood-2022-167732 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Matthew R Lordo;Thanh T Dinh;Nikolas A Shilo;Ekaterina S Altynova;Erin G. Jeremy;Aditi Varkey;Patrick L Collins;Aharon G Freud;Bethany L Mundy-Bosse - 通讯作者:
Bethany L Mundy-Bosse
Erin G. Jeremy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 4.2万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 4.2万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 4.2万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 4.2万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 4.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 4.2万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 4.2万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 4.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 4.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 4.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)